TN2014000337A1 - Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status - Google Patents

Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Info

Publication number: TN2014000337A1
Authority: TN; Tunisia
Prior art keywords: rnf43; znrf3; administration; cancer patient; wnt signaling
Prior art date: 2012-02-28

Application number

TNP2014000337A

Other languages

English (en)

Inventor

Feng Cong

Huaixiang Hao

Hsin-I Hsieh

Xiaomo Jiang

Jun Liu

Nicholas Ng

Original Assignee

Novartis Ag

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-28

Filing date

2014-08-05

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47790546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-05 Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag

2015-12-21 Publication of TN2014000337A1 publication Critical patent/TN2014000337A1/fr

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
201000011510 cancer Diseases 0.000 title abstract 3
102000013814 Wnt Human genes 0.000 title abstract 2
230000035772 mutation Effects 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
230000011664 signaling Effects 0.000 title 1
102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 abstract 4
101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 abstract 3
101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 abstract 3
102000006083 ZNRF3 Human genes 0.000 abstract 3
239000000090 biomarker Substances 0.000 abstract 3
101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 abstract 1
101100091155 Homo sapiens RNF43 gene Proteins 0.000 abstract 1
102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 abstract 1
101150041027 ZNRF3 gene Proteins 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
238000012224 gene deletion Methods 0.000 abstract 1
230000002779 inactivation Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
229940121396 wnt pathway inhibitor Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2014000337A 2012-02-28 2014-08-05 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status TN2014000337A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261604290P	2012-02-28	2012-02-28
PCT/US2013/027441 WO2013130364A1 (fr)	2012-02-28	2013-02-22	Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43

Publications (1)

Publication Number	Publication Date
TN2014000337A1 true TN2014000337A1 (en)	2015-12-21

Family

ID=47790546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2014000337A TN2014000337A1 (en)	2012-02-28	2014-08-05	Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Country Status (20)

Country	Link
US (3)	US20150125857A1 (fr)
EP (2)	EP2820151B1 (fr)
JP (2)	JP6397335B2 (fr)
KR (1)	KR20140132712A (fr)
CN (1)	CN104302782A (fr)
AU (1)	AU2013226323B2 (fr)
BR (1)	BR112014020233A2 (fr)
CA (1)	CA2864306A1 (fr)
CL (1)	CL2014002269A1 (fr)
ES (2)	ES2968742T3 (fr)
HK (1)	HK1199744A1 (fr)
IL (1)	IL233920A0 (fr)
MX (1)	MX2014010265A (fr)
NZ (1)	NZ627864A (fr)
PH (1)	PH12014501930A1 (fr)
RU (2)	RU2636000C2 (fr)
SG (1)	SG11201404492VA (fr)
TN (1)	TN2014000337A1 (fr)
WO (1)	WO2013130364A1 (fr)
ZA (1)	ZA201405553B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012174446A1 (fr)	2011-06-17	2012-12-20	President And Fellows Of Harvard College	Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer
US9296826B2 (en)	2011-10-14	2016-03-29	Novartis Ag	Antibodies and methods for WNT pathway-related diseases
CN104302782A (zh)	2012-02-28	2015-01-21	诺华股份有限公司	利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者
US9713612B2 (en)	2013-03-12	2017-07-25	Curegenix, Inc.	Compounds for treatment of cancer
WO2015145388A2 (fr) *	2014-03-27	2015-10-01	Novartis Ag	Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EA201692100A8 (ru) *	2014-04-21	2018-11-30	ЭББВИ СТЕМСЕНТРКС ЭлЭлСи	Новые антитела против rnf43 и способы их применения
HRP20191826T4 (hr) *	2014-10-08	2022-08-05	Redx Pharma Plc	Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
US20160312207A1 (en) *	2015-04-21	2016-10-27	The Board Of Trustees Of The Leland Stanford Junior University	R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
CA2985813A1 (fr) *	2015-05-26	2016-12-01	Curegenix Corporation	Biomarqueurs tumoraux et leur utilisation
WO2018132572A1 (fr)	2017-01-11	2018-07-19	The Board Of Trustees Of The Leland Stanford Junior University	Molécules de substitution de r-spondine (rspo)
JP7305543B2 (ja) *	2017-01-26	2023-07-10	スロゼンオペレーティング，インコーポレイテッド	組織特異的Ｗｎｔシグナル増強分子およびその使用
WO2019245460A1 (fr) *	2018-06-21	2019-12-26	National University Of Singapore	Stratification de patients cancéreux hébergeant des mutations oncogènes dans l'ubiquitine ligase e3 rnf43
US20210299233A1 (en) *	2018-07-12	2021-09-30	The Children's Medical Center Corporation	Method for treating cancer
CA3141632A1 (fr) *	2019-06-21	2020-12-24	Regeneron Pharmaceuticals, Inc.	Traitement de densite minerale osseuse reduite avec des inhibiteurs de zinc et doigt ring 3 (znrf3)
CN113564249B (zh) *	2020-04-28	2023-06-16	中国科学院分子细胞科学卓越创新中心	CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用
CA3198268A1 (fr)	2020-11-16	2022-05-19	Surrozen Operating, Inc.	Molecules d'amelioration de signaux wnt specifiques du fois et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ573739A (en)	2001-09-18	2010-07-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
KR101031025B1 (ko) *	2002-06-06	2011-04-25	온코세라피 사이언스 가부시키가이샤	사람 결장암에 관계하는 유전자 및 폴리펩티드
ES2361541T3 (es) *	2002-06-06	2011-06-17	Oncotherapy Science, Inc.	Genes y polipéptidos relacionados con cánceres de colon humanos.
WO2004032838A2 (fr) *	2002-10-04	2004-04-22	The Regents Of The University Of California	Methodes de traitement du cancer par inhibition de la signalisation de wnt
WO2004086949A2 (fr)	2003-03-25	2004-10-14	John Wayne Cancer Institute	Marqueurs d'adn utilises dans la gestion du cancer
CN101687005A (zh) *	2004-07-09	2010-03-31	加利福尼亚大学董事会	采用抑制Wnt 16信号转导的试剂治疗癌症的方法
WO2006052128A1 (fr) *	2004-11-10	2006-05-18	Hubrecht Laboratorium	Traitement d’un adénome et/ou d’un adénocarcinome intestinal par inhibition de l’activation de la voie notch
CA2601157A1 (fr)	2005-03-16	2006-09-28	Osi Pharmaceuticals, Inc.	Biomarqueurs predictifs de reponse anticancereuse a des inhibiteurs de kinase de recepteur de facteur de croissance epidermique
UA103918C2 (en) *	2009-03-02	2013-12-10	Айерем Элелси	N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011004379A1 (fr) *	2009-07-10	2011-01-13	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Compositions et méthodes de traitement du cancer
EP2549399A1 (fr)	2011-07-19	2013-01-23	Koninklijke Philips Electronics N.V.	Evaluation d'activité de voie Wnt utilisant un modelage probabilistique d'expression de gène cible
US9296826B2 (en)	2011-10-14	2016-03-29	Novartis Ag	Antibodies and methods for WNT pathway-related diseases
CN104302782A (zh)	2012-02-28	2015-01-21	诺华股份有限公司	利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者
WO2017093478A1 (fr)	2015-12-04	2017-06-08	Boehringer Ingelheim International Gmbh	Polypeptides biparatopiques ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales

2013
- 2013-02-22 CN CN201380011506.6A patent/CN104302782A/zh active Pending
- 2013-02-22 RU RU2014139044A patent/RU2636000C2/ru active
- 2013-02-22 SG SG11201404492VA patent/SG11201404492VA/en unknown
- 2013-02-22 US US14/380,776 patent/US20150125857A1/en not_active Abandoned
- 2013-02-22 WO PCT/US2013/027441 patent/WO2013130364A1/fr active Application Filing
- 2013-02-22 ES ES20154250T patent/ES2968742T3/es active Active
- 2013-02-22 ES ES13707527T patent/ES2797533T3/es active Active
- 2013-02-22 EP EP13707527.1A patent/EP2820151B1/fr active Active
- 2013-02-22 JP JP2014559931A patent/JP6397335B2/ja active Active
- 2013-02-22 RU RU2017120287A patent/RU2017120287A/ru not_active Application Discontinuation
- 2013-02-22 CA CA2864306A patent/CA2864306A1/fr not_active Abandoned
- 2013-02-22 AU AU2013226323A patent/AU2013226323B2/en active Active
- 2013-02-22 EP EP20154250.3A patent/EP3693476B1/fr active Active
- 2013-02-22 BR BR112014020233A patent/BR112014020233A2/pt active Search and Examination
- 2013-02-22 MX MX2014010265A patent/MX2014010265A/es unknown
- 2013-02-22 NZ NZ627864A patent/NZ627864A/en not_active IP Right Cessation
- 2013-02-22 KR KR1020147023667A patent/KR20140132712A/ko not_active Abandoned
2014
- 2014-07-28 ZA ZA2014/05553A patent/ZA201405553B/en unknown
- 2014-07-31 IL IL233920A patent/IL233920A0/en unknown
- 2014-08-05 TN TNP2014000337A patent/TN2014000337A1/fr unknown
- 2014-08-27 CL CL2014002269A patent/CL2014002269A1/es unknown
- 2014-08-27 PH PH12014501930A patent/PH12014501930A1/en unknown
2015
- 2015-01-08 HK HK15100179.6A patent/HK1199744A1/xx not_active IP Right Cessation
2016
- 2016-12-20 US US15/385,088 patent/US20170306409A1/en not_active Abandoned
2018
- 2018-06-26 JP JP2018120856A patent/JP2018172408A/ja active Pending
2019
- 2019-01-28 US US16/259,419 patent/US20190203301A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2968742T3 (es)	2024-05-13
NZ627864A (en)	2015-12-24
PH12014501930A1 (en)	2014-11-24
JP6397335B2 (ja)	2018-09-26
RU2017120287A (ru)	2018-11-15
US20150125857A1 (en)	2015-05-07
CL2014002269A1 (es)	2014-12-19
RU2014139044A (ru)	2016-04-20
EP2820151B1 (fr)	2020-03-25
EP3693476A1 (fr)	2020-08-12
US20170306409A1 (en)	2017-10-26
MX2014010265A (es)	2015-06-23
US20190203301A1 (en)	2019-07-04
IL233920A0 (en)	2014-09-30
JP2018172408A (ja)	2018-11-08
HK1199744A1 (en)	2015-07-17
JP2015511484A (ja)	2015-04-20
RU2636000C2 (ru)	2017-11-17
WO2013130364A1 (fr)	2013-09-06
AU2013226323A1 (en)	2014-09-11
BR112014020233A2 (pt)	2017-07-04
ES2797533T3 (es)	2020-12-02
CA2864306A1 (fr)	2013-09-06
SG11201404492VA (en)	2014-10-30
KR20140132712A (ko)	2014-11-18
CN104302782A (zh)	2015-01-21
AU2013226323B2 (en)	2016-07-14
ZA201405553B (en)	2015-12-23
EP3693476B1 (fr)	2023-10-18
EP2820151A1 (fr)	2015-01-07

Publication	Publication Date	Title
PH12014501930A1 (en)	2014-11-24	Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
Hales et al.	2014	New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia
AU2018256477A1 (en)	2018-11-22	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
MX2022000085A (es)	2022-02-10	Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
EA201500334A1 (ru)	2016-01-29	Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
NZ736853A (en)	2019-09-27	Methods of treating cancer patients with farnesyl transferase inhibitors
TN2014000063A1 (en)	2015-07-01	Kinase inhibitor polymorphs
BR112014023162A8 (pt)	2018-01-16	compostos e métodos para modulação quinase e indicações dos mesmos
PH12013502147A1 (en)	2014-01-13	Bcma-based stratification and therapy for multiple myeloma patients
MX2014001246A (es)	2014-06-11	Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
MX2016007066A (es)	2016-09-08	Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
MX2014005800A (es)	2014-05-30	Mutaciones del receptor notch humano y su uso.
WO2015150472A3 (fr)	2016-01-28	Nouvelles stratégies de traitement du mélanome
EP3284481A4 (fr)	2018-12-19	Agent induisant la mort cellulaire pour des cellules ayant une mutation du gène braf, agent pour inhiber la prolifération desdites cellules et composition pharmaceutique pour le traitement d'un patient souffrant des effets de la prolifération anormale desdites cellules
MX2017002364A (es)	2017-05-17	Terapia de combinacion para tratamiento de cancer.
IN2014MN01945A (fr)	2015-07-10
MX2014014097A (es)	2015-04-13	Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
MX2021000133A (es)	2021-03-25	Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa.
IN2014MN01944A (fr)	2015-07-10
HRP20180130T1 (hr)	2018-04-06	Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras
MX2016004212A (es)	2016-07-11	Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
GB2523211A8 (en)	2019-08-28	MCT protein inhibitor-related prognostic and therapeutic methods
WO2012109233A3 (fr)	2012-10-04	Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein
EA201491780A1 (ru)	2015-01-30	Мутанты c-raf, придающие резистентность к ингибиторам raf
WO2013103836A3 (fr)	2013-09-19	Procédés de traitement du cancer